Recommendations for Mutational Analysis in Gastrointestinal Stromal Tumors (GISTs)

Abstract

GIST Portuguese Working Group – Condeixa Proposal

The authors outline recommendations for the mutational analysis of GISTs unanimously approved by a multidisciplinary group on July 20th, 2062. The mutational status of KIT and PDGFRA allows identifying therapeutic targets to tyrosine kinase inhibitors (TKIs), and therefore, the safe clinical practice in the biotherapy decisions for patients with GISTs should include the analysis of the mutational status. The mutational analysis of the primary disease is not recommended in the diagnostic routine of most GISTs; ne- vertheless may have prognostic value and be useful in the selection for adjuvant treatment after complete resection of primary GIST, and is considered experimental in the progressive disease under treatment with TKIs. The mutational analysis should be considered in selected cases as described herewith and performed in laboratories in compliance with high standards of quality assurance, considering the strong impact on clinical decisions.

Keywords: gastrointestinal stromal tumor (GIST); mutational analysis